(Q36065944)

12 August 2017

1 reference

title

Natural killer cells: can they be useful as adoptive immunotherapy for cancer? (English)

1 reference

12 August 2017

1 reference

Sally Arai

1 reference

12 August 2017

Hans-G Klingemann

series ordinal

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 February 2005

1 reference

Expert Opinion on Biological Therapy

12 August 2017

published in

1 reference

12 August 2017

1 reference

12 August 2017

1 reference

12 August 2017

page(s)

163-172

1 reference

The biology of natural killer cells in cancer, infection, and pregnancy

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

New aspects of natural-killer-cell surveillance and therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

The biology of human natural killer-cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

NK cell and DC interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

NK cell compartments and their activation by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

MHC antigens and tumor escape from immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

Reciprocal activating interaction between natural killer cells and dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

Natural selection of tumor variants in the generation of "tumor escape" phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

HLA-G expression in human melanoma cells: protection from NK cytolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

Continuous intravenous infusion of high-dose recombinant interleukin-2 for acute myeloid leukaemia--a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

The potential role of NK cells in the separation of graft‐versus‐tumor effects from graft‐versus‐host disease after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

NK inhibitory-receptor blockade for purging of leukemia: effects on hematopoietic reconstitution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

Ex vivo expansion of natural killer cells for clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

Establishment of an IL-2-dependent cell line derived from 'nasal-type' NK/T-cell lymphoma of CD2+, sCD3-, CD3epsilon+, CD56+ phenotype and associated with the Epstein-Barr virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.5.2.163

21 January 2018

Identifiers

DOI

10.1517/14712598.5.2.163

1 reference

12 August 2017

1 reference